Prime Medicine to Present at Upcoming Investor Conferences
08 11월 2023 - 10:00PM
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company
committed to delivering a new class of differentiated, one-time
curative genetic therapies, today announced that company management
will present at two upcoming investor conferences:
- Stifel
Healthcare Conference: Fireside Chat by Keith
Gottesdiener, M.D., President and Chief Executive Officer, on
Tuesday, November 14, 2023, at 4:10 p.m. ET in New York, NY.
-
Jefferies London Healthcare Conference: Fireside
Chat by Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer, on
Thursday, November 16, 2023, at 1:30 p.m. GMT (8:30 a.m. ET) in
London, UK.
Live audio webcasts of both presentations will
be available under “Events & Presentations” in the News &
Events section of the Company’s website at www.primemedicine.com.
Replays of each webcast will be available on the Prime Medicine
website for 30 days following each presentation.
About Prime Medicine
Prime Medicine is a leading biotechnology
Company dedicated to creating and delivering the next generation of
gene editing therapies to patients. The Company is leveraging its
proprietary Prime Editing platform, a versatile, precise and
efficient gene editing technology, to develop a new class of
differentiated, one-time, potentially curative genetic therapies.
Designed to make only the right edit at the right position within a
gene while minimizing unwanted DNA modifications, Prime Editors
have the potential to repair almost all types of genetic mutations
and work in many different tissues, organs and cell types.
Prime Medicine is currently progressing a
diversified portfolio of eighteen programs initially focused on
genetic diseases with a fast, direct path to treating patients or
with a high unmet need because they cannot be treated using other
gene-editing approaches. Over time, the Company intends to maximize
Prime Editing’s therapeutic potential and advance potentially
curative therapeutic options to patients for a broad spectrum of
diseases. For more information, please visit
www.primemedicine.com.
© 2023 Prime Medicine, Inc. All rights reserved.
PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are
trademarks of Prime Medicine, Inc. All other trademarks referred to
herein are the property of their respective owners.
Investor Contact
Hannah DeresiewiczStern Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media Contact
Dan Budwick, 1ABdan@1ABmedia.com
Prime Medicine (NASDAQ:PRME)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Prime Medicine (NASDAQ:PRME)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024